On May 29, 2020, Avifavir, the world’s first anti-coronavirus drug based on favipiravir, was registered. In a clinical trial of phases II-III, the drug demonstrated high efficacy and safety for the treatment of patients with COVID-19. The drug was developed and launched with the support of the Russian Direct Investment Fund and the Ministry of Industry and Trade of Russia. Since July 2020, Avifavir has been supplied to more than 15 countries worldwide.